Entellus Medical Inc. (ENTL)

24.00
0.01 0.04
NASDAQ : Health Technology
Prev Close 24.01
Open 24.00
Day Low/High 24.00 / 24.08
52 Wk Low/High 11.47 / 25.58
Volume 43.90K
Avg Volume 351.20K
Exchange NASDAQ
Shares Outstanding 25.65M
Market Cap 615.81M
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ENTL, SCHL, WILC Downgrades: BLL, DLTH, INTL, MDSO, NTLA, PNR Initiations: PVAC Read on to get TheStreet Quant Ratings' detailed report:

The Law Offices Of Vincent Wong Notifies Investors Of An Investigation Of Entellus Medical, Inc. Concerning The Sale Of The Company To Stryker Corporation

The Law Offices Of Vincent Wong Notifies Investors Of An Investigation Of Entellus Medical, Inc. Concerning The Sale Of The Company To Stryker Corporation

The Law Offices of Vincent Wong are investigating the Board of Directors of Entellus Medical, Inc.

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors Of An Investigation Concerning Whether The Sale Of Entellus Medical, Inc. To Stryker Corporation For $24.00 Per Share Is Fair To Shareholders

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors Of An Investigation Concerning Whether The Sale Of Entellus Medical, Inc. To Stryker Corporation For $24.00 Per Share Is Fair To Shareholders

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Entellus Medical, Inc.

ENTL Crosses Above Average Analyst Target

ENTL Crosses Above Average Analyst Target

In recent trading, shares of Entellus Medical Inc have crossed above the average analyst 12-month target price of $18.00, changing hands for $23.99/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Concerning Whether The Sale Of Entellus Medical, Inc. To Stryker Corporation For $24.00 Per Share Is Fair To Shareholders - ENTL

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Concerning Whether The Sale Of Entellus Medical, Inc. To Stryker Corporation For $24.00 Per Share Is Fair To Shareholders - ENTL

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Entellus Medical, Inc.

Anthem Inc. Issues Positive Coverage Decision For Balloon Sinus Dilation

Anthem Inc. Issues Positive Coverage Decision For Balloon Sinus Dilation

Anthem Insurance Plans Covering 40 Million Lives Now Provide Reimbursement for XprESS™ ENT Dilation System for Treating Chronic and Recurrent Acute Sinusitis

Entellus Announces Long-Term Data Confirming The Durable Relief Of Nasal Obstruction Symptoms With Latera® From Spirox®

Entellus Announces Long-Term Data Confirming The Durable Relief Of Nasal Obstruction Symptoms With Latera® From Spirox®

18 and 24-Month Data Reinforces Clinical Benefits Without Cosmetic Downside

Entellus Medical To Report Third Quarter 2017 Financial Results November 1, 2017

Entellus Medical To Report Third Quarter 2017 Financial Results November 1, 2017

Conference call scheduled for Wednesday, November 1, 2017 at 3:30 p.m. CT / 4:30 p.m. ET

ENTL Crosses Above Average Analyst Target

ENTL Crosses Above Average Analyst Target

In recent trading, shares of Entellus Medical Inc have crossed above the average analyst 12-month target price of $19.40, changing hands for $19.50/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

ENTL: Insiders vs. Shorts

ENTL: Insiders vs. Shorts

The most recent short interest data was recently released for the 07/14/2017 settlement date, and Entellus Medical Inc is one of the most shorted stocks of the Russell 3000, based on 8.53 "days to cover" versus the median component at 6.16. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Entellus Medical To Report Second Quarter 2017 Financial Results August 3, 2017

Entellus Medical To Report Second Quarter 2017 Financial Results August 3, 2017

Conference call scheduled for Thursday, August 3, 2017 at 3:30pm CT / 4:30pm ET

Commit To Purchase Entellus Medical At $10, Earn 7.8% Annualized Using Options

Investors considering a purchase of Entellus Medical Inc shares, but cautious about paying the going market price of $13.41/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $10 strike, which has a bid at the time of this writing of 50 cents.

ENTL: Insiders vs. Shorts

The most recent short interest data was recently released for the 04/13/2017 settlement date, and Entellus Medical Inc is one of the most shorted stocks of the Russell 3000, based on 12.65 "days to cover" versus the median component at 5.14. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Entellus Medical To Report First Quarter 2017 Financial Results On May 3, 2017

Conference call scheduled for Wednesday, May 3, 2017 at 3:30pm CT / 4:30pm ET

Entellus Medical Becomes Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.